Viyash Scientific targets ₹1,000 cr EBITDA in 2-3 years, pivots to companion animals

Viyash Scientific's May concall did more than confirm record Q4 numbers — it laid out a strategic roadmap that stretches well beyond the current fiscal. Management pegged the FY27 EBITDA run rate at nearly ₹800 crore, with a ₹1,000 crore target within 2-3 years, built on a deliberate shift toward companion animals and an expanding CDMO franchise. The post-merger synergy outperformance cited suggests margins have room to grow even as the revenue mix evolves. While the numbers were pre-disclosed, the qualitative detail on strategic intent gives a fresher lens to value a mid-cap pharma company shaping its own narrative. The open question is whether operational momentum sustains through the transition — but the call offered enough specificity to make the bull case credible.